Affiliations: [a] Department of Oncology, Mayo Clinic, Rochester, MN, USA | [b] Department of Urology, University of Rochester Medical Center, Rochester, NY, USA | [c] Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA | [d] Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA | [e] Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
Abstract: Objectives:An association of a single nucleotide polymorphism (SNP) of the KLK2 gene (rs198977; c.748C>T; R250W) with risk for developing prostate cancer has been observed. We evaluated the role of R250W SNP for prognosis in prostate cancer. Methods:The c.748C>T SNP was genotyped from blood DNA of 182 patients after completing initial cancer treatments. For evaluating prognosis of genotype groups, associations were performed with Gleason score (GS) and biochemical recurrence free survival (bRFS) in patients demonstrating PSA-recurrence after initial cancer therapy. Results:Overall distribution of the CC, CT and TT genotypes for the SNP was 48%, 44% and 8%, respectively. The distribution of high (8–10), moderate (5–7) and low (2–4) GS among the genotype groups was 17%, 74% and 9% for CC group compared to 25%, 74% and 1% for the CT/TT (P=0.04). Median bRFS time for CT/TT group was 36.5 months compared to 44.5 months for the CC group (P=0.16), while genotype groups combined with morphology revealed significantly different bRFS (P=0.004). Conclusions:This exploratory analysis in prostate cancer patients revealed the W allele of the KLK2 R250W SNP to be less likely associated with low GS morphology. Further studies will be needed to confirm this observation in larger cohorts.
